Generation of Aurachin Derivatives by Whole-Cell Biotransformation and Evaluation of Their Antiprotozoal Properties

The natural product aurachin D is a farnesylated quinolone alkaloid, which is known to possess activity against the causative agent of malaria, Plasmodium spp. In this study, we show that aurachin D inhibits other parasitic protozoa as well. While aurachin D had only a modest effect on Trypanosoma brucei rhodesiense, two other trypanosomatids, T. cruzi and Leishmania donovani, were killed at low micromolar and nanomolar concentrations, respectively, in an in vitro assay. The determined IC50 values of aurachin D were even lower than those of the reference drugs benznidazole and miltefosine. Due to these promising results, we set out to explore the impact of structural modifications on the bioactivity of this natural product. In order to generate aurachin D derivatives with varying substituents at the C-2, C-6 and C-7 position of the quinolone ring system, we resorted to whole-cell biotransformation using a recombinant Escherichia coli strain capable of aurachin-type prenylations. Quinolone precursor molecules featuring methyl, methoxy and halogen groups were fed to this E. coli strain, which converted the substrates into the desired analogs. None of the generated derivatives exhibited improved antiprotozoal properties in comparison to aurachin D. Obviously, the naturally occurring aurachin D features already a privileged structure, especially for the inhibition of the causative agent of visceral leishmaniasis.

[1]  M. Nett,et al.  Biocatalytic production of the antibiotic aurachin D in Escherichia coli , 2022, AMB Express.

[2]  A. Gamble,et al.  Synthesis and Biological Evaluation of Aurachin D Analogues as Inhibitors of Mycobacterium tuberculosis Cytochrome bd Oxidase. , 2022, ACS medicinal chemistry letters.

[3]  R. Weis,et al.  Antiprotozoal Activity of Azabicyclo-Nonanes Linked to Tetrazole or Sulfonamide Cores , 2022, Molecules.

[4]  M. Nett,et al.  Emerging concepts in the semisynthetic and mutasynthetic production of natural products. , 2022, Current opinion in biotechnology.

[5]  Kuljit Singh,et al.  Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets. , 2022, Life sciences.

[6]  S. Peter,et al.  High Plasticity of the Amicetin Biosynthetic Pathway in Streptomyces sp. SHP 22-7 Led to the Discovery of Streptcytosine P and Cytosaminomycins F and G and Facilitated the Production of 12F-Plicacetin. , 2022, Journal of natural products.

[7]  H. Schwalbe,et al.  Short-chain aurachin D derivatives are selective inhibitors of E. coli cytochrome bd-I and bd-II oxidases , 2021, Scientific Reports.

[8]  J. Pietruszka,et al.  Mutasynthesis of Physostigmines in Myxococcus xanthus. , 2021, Organic letters.

[9]  D. Adpressa,et al.  Precursor-Directed Biosynthesis of Aminofulvenes: New Chalanilines from Endophytic Fungus Chalara sp. , 2021, Molecules.

[10]  C. R. Alves,et al.  Axenic amastigotes of Leishmania species as a suitable model for in vitro studies. , 2021, Acta tropica.

[11]  Atukuri Dorababu Quinoline: A Promising Scaffold in Recent Antiprotozoal Drug Discovery , 2021, ChemistrySelect.

[12]  Rachel Tidman,et al.  The impact of climate change on neglected tropical diseases: a systematic review , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[13]  M. Nett,et al.  Bioengineering of Anti‐Inflammatory Natural Products , 2020, ChemMedChem.

[14]  P. Mäser,et al.  HPLC-Based Activity Profiling for Antiprotozoal Compounds in Croton gratissimus and Cuscuta hyalina , 2020, Frontiers in Pharmacology.

[15]  Manish Walia,et al.  Synthesis of (-)-Melodinine K: A Case Study of Efficiency in Natural Product Synthesis. , 2020, Journal of natural products.

[16]  S. Lütz,et al.  Biosynthetic Plasticity Enables Production of Fluorinated Aurachins , 2020, Chembiochem : a European journal of chemical biology.

[17]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[18]  L. Bavia,et al.  Chagas Disease: From Discovery to a Worldwide Health Problem , 2019, Front. Public Health.

[19]  A. Vcev,et al.  Malaria: The Past and the Present , 2019, Microorganisms.

[20]  Greta Volpedo,et al.  Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites , 2018, Front. Microbiol..

[21]  D. Molyneux,et al.  Neglected tropical diseases: progress towards addressing the chronic pandemic , 2017, The Lancet.

[22]  Robert H Bates,et al.  Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. , 2016, Journal of medicinal chemistry.

[23]  A. Saxena,et al.  Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. , 2015, Bioorganic & medicinal chemistry.

[24]  P. Simarro,et al.  Epidemiology of human African trypanosomiasis , 2014, Clinical epidemiology.

[25]  K. Andrews,et al.  Drug repurposing and human parasitic protozoan diseases , 2014, International journal for parasitology. Drugs and drug resistance.

[26]  A. Speicher,et al.  Synthesis of aurachin D and isoprenoid analogues from the myxobacterium Stigmatella aurantiaca , 2013 .

[27]  R. Müller,et al.  Synthesis and biological activities of the respiratory chain inhibitor aurachin D and new ring versus chain analogues , 2013, Beilstein journal of organic chemistry.

[28]  Jay D. Keasling,et al.  Identification and microbial production of a terpene-based advanced biofuel , 2011, Nature communications.

[29]  R. Müller,et al.  AuaA, a Membrane‐Bound Farnesyltransferase from Stigmatella aurantiaca, Catalyzes the Prenylation of 2‐Methyl‐4‐hydroxyquinoline in the Biosynthesis of Aurachins , 2011, Chembiochem : a European journal of chemical biology.

[30]  Umberto D'Alessandro,et al.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria , 2011, Malaria Journal.

[31]  R. Müller,et al.  Completing the puzzle of aurachin biosynthesis in Stigmatella aurantiaca Sg a15. , 2011, Molecular bioSystems.

[32]  Roman Manetsch,et al.  Divergent route to access structurally diverse 4-quinolones via mono or sequential cross-couplings. , 2010, The Journal of organic chemistry.

[33]  Hemantkumar S. Deokar,et al.  Novel quinoline and naphthalene derivatives as potent antimycobacterial agents. , 2010, European journal of medicinal chemistry.

[34]  Q. You,et al.  Microwave-Assisted Simple Synthesis of Substituted 4-Quinolone Derivatives , 2009 .

[35]  B. Kunze,et al.  Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E. , 2008, Journal of natural products.

[36]  R. Kaminsky,et al.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.

[37]  F. Buckner,et al.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase , 1996, Antimicrobial agents and chemotherapy.

[38]  P. Rich,et al.  New inhibitors of the quinol oxidation sites of bacterial cytochromes bo and bd. , 1995, Biochemistry.

[39]  H. Reichenbach,et al.  The aurachins, new quinoline antibiotics from myxobacteria: production, physico-chemical and biological properties. , 1987, The Journal of antibiotics.

[40]  I. Cunningham New culture medium for maintenance of tsetse tissues and growth of trypanosomatids. , 1977, The Journal of protozoology.